4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$68.8 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 43.33% year-over-year to -$68.8 million in Q1 2026; TTM through Mar 2026 was -$160.9 million, a 8.81% increase from a year earlier, with the FY2025 full-year figure at -$140.1 million, up 12.9% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$68.8 million, down from $19.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for FDMT reached as high as $19.4 million in Q4 2025 and fell as low as -$68.8 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$34.0 million across 5 years, with a median of -$32.3 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders sank 327.49% in 2024 and jumped 139.05% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$27.4 million in 2022, then dropped by 17.91% to -$32.3 million in 2023, then plunged by 53.86% to -$49.7 million in 2024, then surged by 139.05% to $19.4 million in 2025, then plunged by 454.49% to -$68.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$68.8 million in Q1 2026, $19.4 million in Q4 2025, and -$56.9 million in Q3 2025.